A phase 1
clinical trial in 2004 demonstrated the safety and tolerability of mapatumumab in cancer patients with advanced solid tumors or
non-Hodgkin’s lymphoma, and supported further evaluation in phase 2 clinical trials, both as a single agent and in combination with chemotherapy. In a phase 2 clinical trial, mapatumumab was well tolerated and could be administered safely in patients with advanced
non-small-cell lung cancer (NSCLC) and advanced
colorectal cancer. Stable disease was observed in a number of NSCLC patients. In two phase 1b clinical trials mapatumumab in combination with chemotherapy was well tolerated by patients with advanced
solid tumors. Partial response was observed in a number of patients in each of the studies. The results of a phase 2 clinical trial demonstrated that mapatumumab was well tolerated and capable of producing clinical responses when administered as
monotherapy in patients with advanced
non-Hodgkin’s lymphoma, according to HGS.
Multiple myeloma In 2008 HGS reported initial results of a randomised phase 2 trial of mapatumumab in combination with
bortezomib in advanced
multiple myeloma. However, in 2010, mapatumumab failed in a midstage study. There was no difference in disease response or progression-free survival rates between patients receiving the drug for multiple myeloma and the control group.
Non-small-cell lung cancer "In August 2008, ... initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (10 mg/kg or 30 mg/kg) in combination with
paclitaxel and
carboplatin as first-line therapy in patients with advanced
non-small-cell lung cancer (NSCLC); initial data from the study are anticipated in 2009."
Liver cancer "In July 2008, HGS initiated dosing in ... a randomized Phase 2 trial of HGS-ETR1 in combination with Nexavar (
sorafenib) in patients with advanced hepatocellular cancer, which accounts for 80-90% of all
liver cancers." == See also==